Bahlis, inna guller, hugo fernandez, mark s. Goodman, kelvin p. Lee, div. Of hematology-oncology,sylvester comprehensive cancer center, univ. Of miami, miami, fl. Abstract: in the treatment of chronic myelogenous leukemia (cml), there is convincing data indicating that the anti-leukemia immune responses can eliminate residual disease and prevent relapse. Cellular vaccination with dendritic cells (dc) loaded with leukemia antigens may induce robust anti-leukemia immune responses. One strategy to generate such antigen-loaded dc is to drive the differentiat.